Skip to content
AnalystLens

Medpace Holdings 8-K Report, Financial Results (Feb 12, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 12, 2024
Period End
February 12, 2024
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 8-K filed February 12, 2024. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (Nasdaq: MEDP) reported fourth-quarter and full-year 2023 results in a press release dated February 12, 2024, furnished as Exhibit 99.1 to this Form 8-K under Item 2.02.

For the fourth quarter, revenue increased 26.5% to $498.4 milliona, net new business awards were $614.7 million (a 1.23x net book-to-bill ratio), and GAAP net income was $78.3 million, or $2.46 per diluted share. EBITDA rose 19.2% to $95.8 million. For the full year 2023, revenue increased 29.2% to $1,885.8 million, GAAP net income was $282.8 million, or $8.88 per diluted share, and EBITDA was $362.5 million.

Backlog as of December 31, 2023 increased 20.2% to $2,813.0 millionb. The company issued 2024 guidance calling for revenue of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue. It expects GAAP net income of $326.0 million to $348.0 million, diluted EPS of $10.18 to $10.87, and EBITDA of $400.0 million to $430.0 million.

The guidance assumes a tax rate of 16.0% to 17.0%, interest income of $18.4 millionc, and 32.0 million diluted shares, and excludes any future share repurchases. On the balance sheet, cash and cash equivalents were $245.4 million at December 31, 2023, up from $28.3 million a year earlier, and operating cash flow for the full year was $433.4 million. The company repurchased 781,068 shares for $144.0 million in 2023 and had $308.8 million remaining under its repurchase program.

The filing also notes a conference call on February 13, 2024 at 9:00 a.m. ET.

Key Highlights

  1. Q4 2023 revenue of $498.4 million, up 26.5% from $394.1 million; constant-currency growth of 26.0%
  2. Q4 2023 net new business awards of $614.7 million, up 26.7%, yielding a net book-to-bill ratio of 1.23x
  3. Full-year 2023 revenue of $1,885.8 million, up 29.2%, with GAAP diluted EPS of $8.88 versus $7.28 in 2022
  4. Backlog at December 31, 2023 of $2,813.0 million, up 20.2% year over year
  5. 2024 guidance: revenue of $2.150–$2.200 billion, GAAP net income of $326.0–$348.0 million, and diluted EPS of $10.18–$10.87
  6. 2024 EBITDA guidance of $400.0–$430.0 million, with a full-year EBITDA margin of 19.2% reported for 2023
  7. Cash of $245.4 million at year-end 2023; $144.0 million of share repurchases in 2023 with $308.8 million remaining authorization

Frequently Asked Questions

  1. How did Medpace perform in the fourth quarter of 2023?

    Revenue rose 26.5% to $498.4 million and GAAP net income was $78.3 million, or $2.46 per diluted share, compared with $68.7 million, or $2.12 per diluted share, a year earlier. EBITDA increased 19.2% to $95.8 million.

  2. What does the 2024 guidance imply for the company?

    Medpace forecasts 2024 revenue of $2.150 billion to $2.200 billion, which the filing states represents growth of 14.0% to 16.7% over 2023. It expects GAAP net income of $326.0 million to $348.0 million and diluted EPS of $10.18 to $10.87.

  3. What were the key new business and backlog metrics?

    Q4 2023 net new business awards were $614.7 million, for a net book-to-bill ratio of 1.23x. Full-year awards were $2,356.7 million, a 1.25x book-to-bill ratio, and backlog at December 31, 2023 reached $2,813.0 million, up 20.2%.

  4. How much capital did the company return to shareholders in 2023?

    Medpace repurchased 781,068 shares for $144.0 million during 2023, with no repurchases in the fourth quarter. As of December 31, 2023, $308.8 million remained under its authorized repurchase program.

  5. What is the status of the company's liquidity?

    Cash and cash equivalents were $245.4 million at December 31, 2023, compared with $28.3 million at the end of 2022. Net cash provided by operating activities for the full year 2023 was $433.4 million.